Bufalin engages in RIP1-dependent and ROS-dependent programmed necroptosis in breast cancer cells by targeting the RIP1/RIP3/PGAM5 pathway

Li, YL; Gong, PC; Kong, CC; Tian, X

Tian, X (reprint author), China Med Univ, Affiliated Hosp 1, Canc Res Inst, Mol Oncol Lab, Shenyang 110001, Liaoning, Peoples R China.

ANTI-CANCER DRUGS, 2019; 30 (7): 706